BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 16220110)

  • 1. CYP2C9, CYP2C19, ABCB1 (MDR1) genetic polymorphisms and phenytoin metabolism in a Black Beninese population.
    Allabi AC; Gala JL; Horsmans Y
    Pharmacogenet Genomics; 2005 Nov; 15(11):779-86. PubMed ID: 16220110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients.
    Argikar UA; Cloyd JC; Birnbaum AK; Leppik IE; Conway J; Kshirsagar S; Oetting WS; Klein EC; Remmel RP
    Epilepsy Res; 2006 Sep; 71(1):54-63. PubMed ID: 16815679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of galactose single-point test levels and phenytoin metabolic polymorphisms with gingival hyperplasia in patients receiving long-term phenytoin therapy.
    Lin CJ; Yen MF; Hu OY; Lin MS; Hsiong CH; Hung CC; Liou HH
    Pharmacotherapy; 2008 Jan; 28(1):35-41. PubMed ID: 18154472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of the CYP2C9 AND CYP2C19 polymorphisms on phenytoin hydroxylation in healthy individuals from south India.
    Rosemary J; Surendiran A; Rajan S; Shashindran CH; Adithan C
    Indian J Med Res; 2006 May; 123(5):665-70. PubMed ID: 16873909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of genetic polymorphisms of CYP2C9 and CYP2C19 on phenytoin metabolism in Japanese adult patients with epilepsy: studies in stereoselective hydroxylation and population pharmacokinetics.
    Mamiya K; Ieiri I; Shimamoto J; Yukawa E; Imai J; Ninomiya H; Yamada H; Otsubo K; Higuchi S; Tashiro N
    Epilepsia; 1998 Dec; 39(12):1317-23. PubMed ID: 9860067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stereoselective 4'-hydroxylation of phenytoin: relationship to (S)-mephenytoin polymorphism in Japanese.
    Ieiri I; Mamiya K; Urae A; Wada Y; Kimura M; Irie S; Amamoto T; Kubota T; Yoshioka S; Nakamura K; Nakano S; Tashiro N; Higuchi S
    Br J Clin Pharmacol; 1997 Apr; 43(4):441-5. PubMed ID: 9146858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The predictive value of MDR1, CYP2C9, and CYP2C19 polymorphisms for phenytoin plasma levels.
    Kerb R; Aynacioglu AS; Brockmöller J; Schlagenhaufer R; Bauer S; Szekeres T; Hamwi A; Fritzer-Szekeres M; Baumgartner C; Ongen HZ; Güzelbey P; Roots I; Brinkmann U
    Pharmacogenomics J; 2001; 1(3):204-10. PubMed ID: 11908757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenytoin metabolic ratio: a putative marker of CYP2C9 activity in vivo.
    Caraco Y; Muszkat M; Wood AJ
    Pharmacogenetics; 2001 Oct; 11(7):587-96. PubMed ID: 11668218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic polymorphisms of CYP2C9 and CYP2C19 in the Beninese and Belgian populations.
    Allabi AC; Gala JL; Desager JP; Heusterspreute M; Horsmans Y
    Br J Clin Pharmacol; 2003 Dec; 56(6):653-7. PubMed ID: 14616425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic variants in CYP (-1A2, -2C9, -2C19, -3A4 and -3A5), VKORC1 and ABCB1 genes in a black South African population: a window into diversity.
    Dandara C; Lombard Z; Du Plooy I; McLellan T; Norris SA; Ramsay M
    Pharmacogenomics; 2011 Dec; 12(12):1663-70. PubMed ID: 22118051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contributions of CYP2C9/CYP2C19 genotypes and drug interaction to the phenytoin treatment in the Korean epileptic patients in the clinical setting.
    Lee SY; Lee ST; Kim JW
    J Biochem Mol Biol; 2007 May; 40(3):448-52. PubMed ID: 17562299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
    Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
    Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human CYP2C-mediated stereoselective phenytoin hydroxylation in Japanese: difference in chiral preference of CYP2C9 and CYP2C19.
    Yasumori T; Chen LS; Li QH; Ueda M; Tsuzuki T; Goldstein JA; Kato R; Yamazoe Y
    Biochem Pharmacol; 1999 Jun; 57(11):1297-303. PubMed ID: 10230773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population estimation of the effects of cytochrome P450 2C9 and 2C19 polymorphisms on phenobarbital clearance in Japanese.
    Goto S; Seo T; Murata T; Nakada N; Ueda N; Ishitsu T; Nakagawa K
    Ther Drug Monit; 2007 Feb; 29(1):118-21. PubMed ID: 17304159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acenocoumarol sensitivity and pharmacokinetic characterization of CYP2C9 *5/*8,*8/*11,*9/*11 and VKORC1*2 in black African healthy Beninese subjects.
    Allabi AC; Horsmans Y; Alvarez JC; Bigot A; Verbeeck RK; Yasar U; Gala JL
    Eur J Drug Metab Pharmacokinet; 2012 Jun; 37(2):125-32. PubMed ID: 21811894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population.
    Gaikovitch EA; Cascorbi I; Mrozikiewicz PM; Brockmöller J; Frötschl R; Köpke K; Gerloff T; Chernov JN; Roots I
    Eur J Clin Pharmacol; 2003 Aug; 59(4):303-12. PubMed ID: 12879168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cytochrome P-450 2C9/2C19 but not the ABCB1 genetic polymorphism may be associated with the liver cytochrome 3A4 induction by phenytoin.
    Chhun S; Verstuyft C; Rizzo-Padoin N; Simoneau G; Becquemont L; Bergmann JF; Mouly S
    J Clin Psychopharmacol; 2012 Jun; 32(3):429-31. PubMed ID: 22561479
    [No Abstract]   [Full Text] [Related]  

  • 18. [Association between genetic polymorphisms of CYP2C19 and CYP2C9 and phenytoin serum concentration].
    Huang Y; Yang JF; Qi XL; Wang YQ; Wang WZ; Chen B
    Zhonghua Yi Xue Za Zhi; 2004 Oct; 84(20):1686-9. PubMed ID: 15569425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C9, CYP2C19, and ABCB1 genotype and hospitalization for phenytoin toxicity.
    Hennessy S; Leonard CE; Freeman CP; Metlay JP; Chu X; Strom BL; Bilker WB
    J Clin Pharmacol; 2009 Dec; 49(12):1483-7. PubMed ID: 19617466
    [No Abstract]   [Full Text] [Related]  

  • 20. Urinary excretion of phenytoin metabolites, 5-(4'-hydroxyphenyl)-5-phenylhydantoin and its O-glucuronide in humans and analysis of genetic polymorphisms of UDP-glucuronosyltransferases.
    Yamanaka H; Nakajima M; Hara Y; Katoh M; Tachibana O; Yamashita J; Yokoi T
    Drug Metab Pharmacokinet; 2005 Apr; 20(2):135-43. PubMed ID: 15855726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.